Mednet Logo
SpecialtiesPrimary Care
Primary Care

Primary Care

Physician perspectives on preventive care, chronic disease management, and evidence-based primary care practice.

Recent Discussions

How do you decide between obtaining routine, outpatient ETT versus stress TTE when screening for CAD, especially given insurance company preference on ETTs? 

1 Answers

Mednet Member
Mednet Member
Cardiology · Ohio State University Cardiovascular Medicine

Before getting into the opinion on the above question, it has to be said that the practice of utilizing any stress test to "screen" for coronary artery disease is currently frowned upon, and it is recommended that proceeding with a diagnostic workup should be based on the patient being both at risk ...

Is there a role for 24 hour urine stone risk profiles in your patients with known recurrent struvite kidney stones?

1
2 Answers

Mednet Member
Mednet Member
Nephrology · Mayo Clinic

It depends. Pure struvite stones are not a metabolic abnormality; they are the consequence of a urease-producing urinary infection that splits urea to ammonium, raising the urine pH into the high 7-8 range, which in turn precipitates magnesium ammonium phosphate, otherwise known as struvite. Pure st...

How do you discuss the benefits and potential risks of anticoagulation for a strong indication (e.g., atrial fibrillation with high CHA2DS2-Vasc score) with older adult patients with frequent falls?

1 Answers

Mednet Member
Mednet Member
Geriatric Medicine · University of California San Francisco

Current guidelines from AHA/ACC emphasize that oral anticoagulants should not be withheld simply because a patient is at risk of falling.Instead, I try to manage involving shared decision-making with the patient or DPOA that weighs stroke risk against modifiable bleeding and fall risk factors( with ...

Do you routinely check serum phosphorus levels after IV iron therapy?

1
2 Answers

Mednet Member
Mednet Member
Hematology · Georgetown University School of Medicine

Only before and after FCM. I hold subsequent doses if phosphorus low. There is no need to monitor with the other formulations. For people needing multiple doses of IV iron (IBD, bariatric surgery, heavy uterine bleeding, angiodysplasia), I avoid FCM.

What varying approaches do you take in suicide risk assessments?

2
4 Answers

Mednet Member
Mednet Member
Psychiatry · Northwell Health

I agree with the following from Dr. @Dr. First Last: "Ultimately, no scale or method is going to be perfect. We are unfortunately bad at predicting which individuals with suicidal ideation progress to an attempt. The most we can do is gather as much information as possible about how someone is feeli...

Does the presence of diastolic dysfunction guide subsequent pharmacological, pacing and ablative therapies for atrial fibrillation?

1 Answers

Mednet Member
Mednet Member
Cardiology · Uva Health Heart And Vascular Center Fontaine

For the majority of patients with atrial fibrillation, symptoms are generated by the elevated heart rates rather than the irregularity or the loss of the atrial contribution to ventricular filling. The exception to this is patients with heart failure with preserved ejection fraction (diastolic dysfu...

How do you decide between atorvastatin versus rosuvastatin and their high-intensity doses for statin-naive patients following a STEMI and PCI?

1
4 Answers

Mednet Member
Mednet Member
Cardiology · The George Washington University Hospital

20 mg of Crestor is highly effective and tolerable.

How do you decide between atorvastatin versus rosuvastatin and their high-intensity doses for statin-naive patients following a STEMI and PCI?

1
4 Answers

Mednet Member
Mednet Member
Cardiology · The George Washington University Hospital

20 mg of Crestor is highly effective and tolerable.

Do you monitor CBCs to assess for drug toxicity in patients on nintedanib?

2
1 Answers

Mednet Member
Mednet Member
Pulmonology · University of North Carolina @ Chapel Hill

Not typically. I've never been advised to check these, but it's worth re-examining whether it's worthwhile. Looking at the side effect profile in INBUILD and INPULSIS doesn't reveal any major cytopenias. It doesn't appear to be on the FDA prescription information, either. I think this question arise...

Do you recommend starting a statin in patients above 75 years old with diabetes but no known ASCVD?

7
3 Answers

Mednet Member
Mednet Member
Geriatric Medicine · UT Southwestern

The time to benefit (TTB) for statins in primary prevention of cardiovascular events is generally about 1.5 to 3 years. This means that adults aged 50 to 75 years typically need to take statins for at least 2.5 years to achieve a meaningful reduction in major adverse cardiovascular events (MACE), su...